Azilsartan medoxomil
-
Azilsartan medoxomil
structure -
-
CAS No:
863031-21-4
-
Formula:
C30H24N4O8
-
Chemical Name:
Azilsartan medoxomil
-
Synonyms:
1H-Benzimidazole-7-carboxylic acid,1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1′-biphenyl]-4-yl]methyl]-2-ethoxy-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;Azilsartan medoxomil;TAK 491;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-[[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate;Edarbi;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate;Ipreziv
- Categories:
-
CAS No:
Description
Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension. IC50 Value: 0.62 nM [2]Target: AT1 receptorin vitro: In aortic endothelial cells, azilsartan inhibited cell proliferation at concentrations as low as 1 μmol/l, whereas valsartan showed little or no antiproliferative effects at concentrations below 10 μmol/l. Antiproliferative effects of azilsartan were a
Azilsartan medoxomil is a carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension. It has a role as a prodrug, an angiotensin receptor antagonist and an antihypertensive agent. It is a member of benzimidazoles, a dioxolane, a cyclic carbonate ester, a 1,2,4-oxadiazole, an aromatic ether and a carboxylic ester. It derives from an azilsartan. It is a conjugate acid of an azilsartan medoxomil(1-).|Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as "Edarbi" by Takeda. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure.|Azilsartan Medoxomil is a medoxomil prodrug of azilsartan, an angiotensin II receptor antagonist with antihypertensive activity. Upon hydrolysis, azilsartan selectively and competitively binds to the AT1 subtype angiotensin II receptor and blocks the binding of angiotensin II to the receptor, thus promoting vasodilatation and counteracting the effects of aldosterone. Converted from angiotensin I by angiotensin-converting enzyme (ACE), angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, decreasing sodium excretion and increasing potassium excretion, and acts as a vasoconstrictor in vascular smooth muscle.
Azilsartan medoxomil Basic Attributes
568.53356
568.53
1308068-626-2
LL0G25K7I2
DTXSID10235482
C75110
C09CA09|C - Cardiovascular system
Characteristics
140
4.9
1.5±0.1 g/cm3
212-214
748.0±70.0°C at 760 mmHg
406.2±35.7 °C
1.680
Practically insoluble in water
6.1None
6.1
Toxicity
Hypotension and diarrhea are most common.
Azilsartan medoxomil is 99% plasma protein bound.
Drug Information
Treatment of hypertension (alone or as an adjunct).|FDA Label|Edarbi is indicated for the treatment of essential hypertension in adults.|Ipreziv is indicated for the treatment of essential hypertension in adults.|Treatment of hypertension
Azilsartan medoxomil decreases the pressor effect of angiotensin II. In response, angiotensin I, angiotensin II, and renin are increased while aldosterone is decreased.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)
Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours.|Renal clearance is 2.3 L/minute.|Azilsartan medoxomil has a Vd of 16L.|Fecal elimination accounts for 55%, urine excretion 42%, and unchanged drug 15%.
Azilsartan is metabolized by CYP2C9. CYP2C9 carries out decarboxylation of azilsartan to M-I, and O-dealkylation of azilsartan to M-II. Both M-I and M-II have no pharmacologic activity.
The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.
Azilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features.
azilsartan medoxomil
Azilsartan medoxomil Use and Manufacturing
Human drugs -> Edarbi -> EMA Drug Category|Agents acting on the renin-angiotensin system -> Human pharmacotherapeutic group|Human drugs -> Ipreziv -> EMA Drug Category|Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:568.5
XLogP3:4.9
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:10
Exact Mass:568.15941374
Monoisotopic Mass:568.15941374
Topological Polar Surface Area:140
Heavy Atom Count:42
Complexity:1100
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of Azilsartan medoxomil
-
CN
5 YRS
Business licensedTrader Supplier of PVC resin,pvc paste resin,melamineInquiryCAS No.: 863031-21-4Grade: Industrial GradeContent: 99% -
CN
3 YRS
Business licensed Certified factoryManufactory Supplier of Dyes,Textile agent,Medical intermediate,API,Pigments,Basic Chemicals
Latest News on Azilsartan medoxomil
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Faropenem medoxomil
141702-36-5
-
Azilsartan
147403-03-0
-
Azilsartan kamedoxomil
863031-24-7
-
Olmesartan medoxomil Formula
144689-63-4
-
Tritylolmesartan medoxomil Formula
144690-92-6
-
Azilsartan pharMaceutical interMediate Formula
136304-78-4
-
Dabrafenib Structure
1195765-45-7
-
BOC-VAL-VAL-OH Structure
69209-73-0
-
What is BMS 303141
943962-47-8
-
What is (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
60117-17-1